Cenobamate - SK biopharmaceuticals

Drug Profile

Cenobamate - SK biopharmaceuticals

Alternative Names: YKP 3089

Latest Information Update: 09 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SK biopharmaceuticals
  • Class Analgesics; Antidepressants; Antiepileptic drugs; Anxiolytics; Azoles; Carbamates; Mood stabilisers; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Partial epilepsies
  • Phase II Bipolar disorders; Neuropathic pain
  • Phase I Anxiety disorders

Most Recent Events

  • 02 Nov 2018 SK biopharmaceuticals announces intention to launch cenobamate for Partial epilepsies
  • 20 Sep 2018 SK Life Science plans a phase III trial for Generalised epilepsy in September 2018 (PO) (NCT03678753)
  • 11 Jul 2018 SK Biopharmaceuticals completes the phase I YKP3089C031 trial in Neuropathic pain, Epilepsy and Anxiety disorders (In volunteers) in South Korea (PO) (KCT0002880)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top